NCT01458236View on ClinicalTrials.gov

A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

November 30, 2011

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

Beraprost Sodium 314d Modified Release Tablets

Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration

DRUG

Placebo

Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group